UK – NICE U-turn for Epidyolex in epilepsy

The National Institute for Health and Care Excellence (NICE) has recommended GW Pharma's Epidyolex (cannabidiol) for two rare, severe forms of childhood-onset epilepsy.

Initially the organisation rejected the cannabinoid prescription medicine but promised to “work with the company to resolve the economic modelling issues identified by the committee, and to help them understand what they may need to do to mitigate the cost of cannabidiol to the NHS.”

Now, NICE has recommended the drug in combination with clobazam for Lennox Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older.

The news is being hailed as a “momentous occasion for UK patients and families who have waited for so many years for rigorously tested, evidenced and regulatory approved cannabis-based medicines to be reimbursed by the NHS,” said Chris Tovey, GW’s chief operating officer…